Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma.

brachytherapy chemoradiotherapy dose escalation esophageal cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Jul 2023
Historique:
received: 10 05 2023
revised: 22 06 2023
accepted: 10 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

This study aims to investigate the effect of dose escalation with brachytherapy (BT) as an addition to definitive chemoradiotherapy (CRT) on local control and survival in esophageal cancer. From 2001 to 2020, 183 patients with locally limited or locally advanced esophageal cancer received definitive CRT with or without brachytherapy in a two-center study. External-beam radiotherapy was delivered at 50.4 Gy in 1.8 Gy daily fractions, followed by a sequential boost to the primary tumor of 9 Gy in 1.8 Gy daily fractions if indicated. Intraluminal high dose rate (HDR) Ir-192 brachytherapy was performed on 71 patients at 10 Gy in two fractions, with one fraction per week. The combined systemic therapy schedules used included 5-fluorouracil/cisplatin or 5-fluorouracil alone. Cisplatin was not administered in patients receiving brachytherapy. The median local progression-free survival was significantly extended in the BT group (18.7 vs. 6.0 months;

Identifiants

pubmed: 37509257
pii: cancers15143594
doi: 10.3390/cancers15143594
pmc: PMC10377190
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer. 1999 Jul 15;86(2):220-8
pubmed: 10421257
J Contemp Brachytherapy. 2022 Jun;14(3):299-309
pubmed: 36199996
Brachytherapy. 2012 Mar-Apr;11(2):130-6
pubmed: 21700506
Cancer Manag Res. 2018 Aug 14;10:2675-2682
pubmed: 30147366
Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59
pubmed: 9539559
Radiother Oncol. 2012 Feb;102(2):303-8
pubmed: 21885139
Int J Clin Oncol. 2012 Jun;17(3):263-71
pubmed: 21748259
J Clin Gastroenterol. 2005 Jul;39(6):495-500
pubmed: 15942435
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1456-61
pubmed: 16863928
Cancer. 2000 Mar 1;88(5):988-95
pubmed: 10699886
Brachytherapy. 2013 Sep-Oct;12(5):463-70
pubmed: 23434221
JAMA. 1999 May 5;281(17):1623-7
pubmed: 10235156
Clin Transl Oncol. 2007 Jun;9(6):385-91
pubmed: 17594953
Strahlenther Onkol. 2007 Feb;183(2):94-8
pubmed: 17294114
Int J Radiat Oncol Biol Phys. 1992;22(5):1043-6
pubmed: 1555950
J Clin Oncol. 2002 Mar 1;20(5):1167-74
pubmed: 11870157
Radiother Oncol. 1987 May;9(1):13-20
pubmed: 3602426
Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):127-32
pubmed: 9212013
J Contemp Brachytherapy. 2015 Dec;7(6):453-61
pubmed: 26816502
Tumori. 2005 Sep-Oct;91(5):406-14
pubmed: 16459637
Brachytherapy. 2022 Sep-Oct;21(5):703-711
pubmed: 35787969
Clin Oncol (R Coll Radiol). 2015 Jan;27(1):56-64
pubmed: 25306490
J Cancer Res Ther. 2014 Apr-Jun;10(2):337-41
pubmed: 25022388
Br J Cancer. 1996 Nov;74(9):1452-7
pubmed: 8912544
Dis Esophagus. 2015 Jul;28(5):453-9
pubmed: 24725186
Expert Rev Anticancer Ther. 2015;15(10):1157-69
pubmed: 26235427
Cancers (Basel). 2023 Apr 28;15(9):
pubmed: 37173988
Eur Rev Med Pharmacol Sci. 2020 Jul;24(14):7589-7597
pubmed: 32744685
J Clin Oncol. 2021 Sep 1;39(25):2816-2824
pubmed: 34101496
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):623-8
pubmed: 10524414
J Contemp Brachytherapy. 2017 Feb;9(1):30-35
pubmed: 28344601
Cancer. 2012 May 15;118(10):2632-40
pubmed: 22565611
Radiother Oncol. 1999 May;51(2):133-9
pubmed: 10435804
Ann Oncol. 2013 Jan;24(1):165-71
pubmed: 22887465
Cancer Res Treat. 2017 Jul;49(3):669-677
pubmed: 27737537
Brachytherapy. 2020 Jul - Aug;19(4):499-509
pubmed: 32444283
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1106-11
pubmed: 16504758
Acta Oncol. 2002;41(1):63-8
pubmed: 11990521
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):769-75
pubmed: 9240645
Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):758-64
pubmed: 16199311
Radiother Oncol. 2002 Jul;64(1):41-5
pubmed: 12208574
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):985-993
pubmed: 27869098

Auteurs

Julian Mangesius (J)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Katharina Hörmandinger (K)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Robert Jäger (R)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Sergej Skvortsov (S)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Marlen Plankensteiner (M)

Department of Radiotherapy, State Hospital of Bolzano, 39100 Bolzano, Italy.

Martin Maffei (M)

Department of Radiotherapy, State Hospital of Bolzano, 39100 Bolzano, Italy.

Thomas Seppi (T)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Daniel Dejaco (D)

Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.
Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Matthias Santer (M)

Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.
Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Manuel Sarcletti (M)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Ute Ganswindt (U)

Department of Radiation Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Comprehensive Cancer Center Innsbruck (CCCI), 6020 Innsbruck, Austria.

Classifications MeSH